ArticleFuture oncology (London, England)2021

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

Aditya Bardia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.